SCHEMBL3896941

SCHEMBL3896941

CC(C#N)(NC(=O)C1(OC(=O)NCc2ccccc2)CCCCC1)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CTSS P25774 5/20 0.45
CTSB P07858 4/20 0.45
CTSL P07711 3/20 0.45
PLAU P00749 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CTSK P43235 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MCL1 Q07820 1/20 0.34
ALDH1A1 P00352 1/20 0.34
EPHX1 P07099 1/20 0.34
HPGD P15428 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
RIPK1 Q13546 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898218 0.87 CTSS (0.46) CTSSCTSBCTSLPLAUSMN1; SMN2
SCHEMBL3893012 0.86 CTSS (0.46) CTSSCTSBCTSLCTSK
SCHEMBL3898220 0.85 CTSS (0.43) CTSSCTSBCTSLPLAUSMN1; SMN2
SCHEMBL3909371 0.83 ALDH1A1 (0.41) CTSSCTSBCTSLSMN1; SMN2CTSK
SCHEMBL3895588 0.81 MEN1 (0.45) CTSSCTSBCTSLSMN1; SMN2MEN1
SCHEMBL3908088 0.81 CTSB (0.41) CTSSCTSBCTSLCTSKMCL1
SCHEMBL3894554 0.81 CTSB (0.38) CTSSCTSBCTSLSMN1; SMN2CTSK
SCHEMBL3898239 0.80 CTSL (0.57) CTSSCTSBCTSLSMN1; SMN2CTSK
SCHEMBL4389776 0.77 SMN1; SMN2 (0.43) CTSSCTSBCTSLSMN1; SMN2CTSK
SCHEMBL3893533 0.76 CTSL (0.48) CTSSCTSBCTSLCTSKMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP claimed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US claimed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US claimed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO claimed
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP disclosed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US disclosed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US disclosed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases NOS1, CTSK, CTSS CTSS 3/4885CTSB 4/4885CTSL 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.